WO2009012784A3 - Procédés de préparation de complexes cytotoxiques d'émulsifiant et d'acide gras - Google Patents

Procédés de préparation de complexes cytotoxiques d'émulsifiant et d'acide gras Download PDF

Info

Publication number
WO2009012784A3
WO2009012784A3 PCT/DK2008/050182 DK2008050182W WO2009012784A3 WO 2009012784 A3 WO2009012784 A3 WO 2009012784A3 DK 2008050182 W DK2008050182 W DK 2008050182W WO 2009012784 A3 WO2009012784 A3 WO 2009012784A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
emulsifier
fatty acid
complexes
malignant
Prior art date
Application number
PCT/DK2008/050182
Other languages
English (en)
Other versions
WO2009012784A2 (fr
Inventor
Teit Agger
Christoffer Bro
Original Assignee
Nya Hamlet Pharma Ab
Teit Agger
Christoffer Bro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nya Hamlet Pharma Ab, Teit Agger, Christoffer Bro filed Critical Nya Hamlet Pharma Ab
Publication of WO2009012784A2 publication Critical patent/WO2009012784A2/fr
Publication of WO2009012784A3 publication Critical patent/WO2009012784A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés de préparation de complexes d'émulsifiants et d'acides gras, qui présentent un effet destructeur sur des cellules, en particulier des cellules tumorales ou autres cellules malignes. Les procédés comprennent le mélange d'un émulsifiant avec un acide gras en utilisant un mélange par cisaillement élevé. L'émulsifiant peut être l'alpha-lactalbumine et l'acide gras peut être de l'acide oléique. Les complexes obtenus selon les procédés peuvent être utilisés dans le traitement d'une variété de maladies caractérisées par la présence de cellules non souhaitées, telles que diverses maladies et infections malignes ou prémalignes, en particulier des infections virales.
PCT/DK2008/050182 2007-07-20 2008-07-21 Procédés de préparation de complexes cytotoxiques d'émulsifiant et d'acide gras WO2009012784A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200701076 2007-07-20
DKPA200701076 2007-07-20

Publications (2)

Publication Number Publication Date
WO2009012784A2 WO2009012784A2 (fr) 2009-01-29
WO2009012784A3 true WO2009012784A3 (fr) 2009-04-09

Family

ID=40280844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050182 WO2009012784A2 (fr) 2007-07-20 2008-07-21 Procédés de préparation de complexes cytotoxiques d'émulsifiant et d'acide gras

Country Status (1)

Country Link
WO (1) WO2009012784A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009135494A2 (fr) * 2008-05-09 2009-11-12 Nya Hamlet Pharma Ab Composition d'alpha-lactalbumine destinée au traitement de la kératose actinique
US20110208153A1 (en) * 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
US20120115955A1 (en) * 2010-10-04 2012-05-10 Centro De Investigacion Principe Felipe Methods for tumor treatment and adipogenesis differentiation
WO2012116453A1 (fr) 2011-03-03 2012-09-07 Zymeworks Inc. Conception et constructions d'échafaudage hétéromultimère multivalent
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
EP2882446B1 (fr) 2012-08-09 2018-05-09 HAMLET Pharma AB Thérapie prophylactique et nutraceutique
US20160220587A1 (en) * 2013-06-21 2016-08-04 David Noakes Vitamin d complexes with de-vdbp and an unsaturated fatty acid, and their use in therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072771A1 (fr) * 2004-01-23 2005-08-11 The Foundation For The Lsu Health Sciences Center Complexe neuroprotecteur destine au traitement de l'ischemie et de lesions cerebrales
WO2008058547A2 (fr) * 2006-11-17 2008-05-22 Nya Hamlet Pharma Ab Composition d'alpha-lactalbumine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072771A1 (fr) * 2004-01-23 2005-08-11 The Foundation For The Lsu Health Sciences Center Complexe neuroprotecteur destine au traitement de l'ischemie et de lesions cerebrales
WO2008058547A2 (fr) * 2006-11-17 2008-05-22 Nya Hamlet Pharma Ab Composition d'alpha-lactalbumine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARBANA ET AL: "Interaction of bovine alpha-lactalbumin with fatty acids as determined by partition equilibrium and fluorescence spectroscopy", INTERNATIONAL DAIRY JOURNAL, ELSEVIER APPLIED SCIENCE, BARKING, GB, vol. 16, no. 1, 1 January 2006 (2006-01-01), pages 18 - 25, XP005130350, ISSN: 0958-6946 *
GUSTAFSSON L ET AL: "TREATMENT OF SKIN PAPILLOMAS WITH TROPICAL ALPHA-LACTALBUMIN-OLEIC ACID", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 350, no. 26, 24 June 2004 (2004-06-24), pages 2663 - 2672, XP008052523, ISSN: 1533-4406 *
MOK ET AL: "HAMLET, protein folding, and tumor cell death", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 354, no. 1, 23 January 2007 (2007-01-23), pages 1 - 7, XP005736132, ISSN: 0006-291X *
PETTERSSON ET AL: "alpha-Lactalbumin species variation, HAMLET formation, and tumor cell death", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 345, no. 1, 23 June 2006 (2006-06-23), pages 260 - 270, XP005438124, ISSN: 0006-291X *
SVENSSON MALIN ET AL: "Lipids as cofactors in protein folding: Stereo-specific lipid-protein interactions are required to form HAMLET (human alpha-lactalbumin made lethal to tumor cells)", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 12, no. 12, 1 December 2003 (2003-12-01), pages 2805 - 2814, XP002455419, ISSN: 0961-8368 *

Also Published As

Publication number Publication date
WO2009012784A2 (fr) 2009-01-29

Similar Documents

Publication Publication Date Title
WO2009012784A3 (fr) Procédés de préparation de complexes cytotoxiques d'émulsifiant et d'acide gras
WO2008058547A3 (fr) Composition d'alpha-lactalbumine
WO2014028453A3 (fr) Cellules tueuses naturelles et leurs utilisations
EP4332576A3 (fr) Amélioration synergique de l'administration d'acides nucléiques par l'intermédiaire de formulations mélangées
WO2013029013A8 (fr) Souches de bacillus produisant une enzyme
WO2013105101A8 (fr) Nanoparticules lipidiques solides encapsulant un médicament hydrophile/amphiphile et leur procédé de préparation
WO2012135805A3 (fr) Administration et formulation d'acides nucléiques génétiquement modifiés
WO2013040078A3 (fr) Tissus artificiels pour des utilisations en recherche in vitro, puces de ces tissus et procédés de fabrication correspondants
WO2010025321A3 (fr) Procédé de traitement de patients souffrant de sclérose en plaques avec des anticorps anti-il2r
WO2006029081A3 (fr) Conjugues nucleoside-lipide, leur procede de preparation, et leurs utilisations
WO2011017151A3 (fr) Méthodes d'appariement pour la préparation de lymphocytes t cytotoxiques alloréactifs
WO2011035335A3 (fr) Compositions d'adamts13 liquides stabilisées et lyophilisées
WO2019066577A3 (fr) Composition pour le diagnostic et le traitement d'une maladie hépatique alcoolique, utilisant une communauté bactérienne intestinale produisant un changement d'acides gras à chaîne courte
WO2009151907A3 (fr) Compositions et procédés permettant d'utiliser des cellules pour traiter le tissu cardiaque
WO2015191934A3 (fr) Barrière hémato-encéphalique pénétrant des protéines de liaison spécifiques doubles pour le traitement de maladies cérébrales et neurologiques
WO2015152693A3 (fr) Nouvel oligo-arn à double brin et composition pharmaceutique le comprenant pour la prévention ou le traitement de la fibrose ou de maladies respiratoires
WO2012040804A3 (fr) Combinaisons synergiques de triazoles, strobilurines et de benzimidazoles, leurs utilisations, formulations, leurs procédés de production et leurs applications
WO2013058594A3 (fr) Procédé de préparation d'un extrait de bois de cerf fermenté ayant une activité anti-inflammatoire, extrait obtenu par le procédé et utilisation d'un tel extrait
WO2010088450A3 (fr) Procédés de traitement de maladies associées à la modulation de serca
WO2012017323A3 (fr) Composition pharmaceutique et méthodes de traitement et de prévention des maladies provoquées par le vih ou associées au vih
WO2008108808A3 (fr) Complexes dérivés de cellules hétérohybrides et utilisations de ceux-ci
MX2021005745A (es) Nanoparticulas y polvos alimentarios derivados de tejidos vegetales.
WO2014008181A8 (fr) Matrice musculaire décellularisée
EP4233896A3 (fr) Procédé de préparation d'un lysat immunogène, lysat obtenu, cellules dendritiques chargées d'un tel lysat et composition pharmaceutique comprenant le lysat ou les cellules dendritiques
WO2009012785A3 (fr) Complexes d'un agent émulsionnant et d'un acide gras

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08773318

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19.05.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08773318

Country of ref document: EP

Kind code of ref document: A2